




PCT/EP200 4 / 0 0 7 6 6 7
08.07.04



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)




The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andrew Cuy*

Dated 15 June 2004

BEST AVAILABLE COPY

Patents Act 1977
(Rule 16)



**The
Patent
Office**

PCT/EP 2001/00700+

08.07.04

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport

Gwent NP9 1RH

11JUL03 E821789-1 001030

P01/7700 0.00-0316206.2

1. Your Reference

SJB/PB60333P

2. Patent application number

(The Patent office will fill in this part)

10 JUL 2003

0316206.2

3. Full name, address and postcode of the or of each applicant (underline all surnames)

GLAXO GROUP LIMITED
GLAXO WELLCOME HOUSE
BERKELEY AVENUE
GREENFORD
MIDDLESEX
UB6 ONN
GB

00473 587 002

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its corporation

GB

4 Title of the invention

PHARMACEUTICAL FORMULATION

5 Name of your agent (if you know one)

SUZANNE BAKER

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

GLAXOSMITHKLINE
CORPORATE INTELLECTUAL PROPERTY (CN9 25.1)
980 GREAT WEST ROAD
BRENTFORD
MIDDLESEX
TW8 9GS

08072555 004

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of Filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant a patent required in support of this request? (Answer yes if:

YES

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Description	12 /
Claim(s)	2 /
Abstract	1 /
Drawing(s)	0

CP

10. If you are also filing any of the following, state how many against each item

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patent Form 9/77*)

Request for substantive examination (*Patent Form 10/77*)

Any other documents
(please specify)

11.

Suzanne Baker

I/We request the grant of a patent on the basis of this application

Signature **SUZANNE BAKER** 10 July 2003
AGENT FOR THE APPLICANTS

12. Name and daytime telephone number of person to contact in the United Kingdom

AMANDA WILKINSON
020 8047 4493

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the patent Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been received

a) Notes

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form

If you have answered "Yes" Patents Form 7/77 will need to be filed.

d) Once you have filled in the form you must remember to sign and date it.

e) For details of the fee and ways to pay please contact the Patent Office.

PHARMACEUTICAL FORMULATION

The present invention relates to stable pharmaceutical formulations of levothyroxine sodium, useful in the treatment of thyroid hormone disorders in mammals, including humans. The invention also relates to a process for preparing such a formulation.

Levothyroxine sodium is widely used in the treatment and/or prophylaxis of thyroid hormone disorders. Levothyroxine sodium is presently commercially available under the trademark Eltroxin™ in the form of 50µg and 100µg tablets. These tablets contain levothyroxine sodium, lactose, magnesium stearate, acacia powder, sodium citrate and maize starch. Whilst levothyroxine sodium is relatively stable in pure form, pharmaceutical formulations containing levothyroxine sodium exhibit a relatively short shelf life, particularly under conditions of high light, heat, air and humidity (see "Kinetics of Degradation of Levothyroxin Sodium in Aqueous solution and in Solid State", Chong Min Won, Pharmaceutical Research, Vol. 9, No 1, (1992), 131-137). The present invention is therefore directed at providing a stable solid dosage form of levothyroxine sodium. It is also desired that the solid dosage form disintegrates rapidly, thereby ensuring rapid release of the active ingredient, and is aesthetically acceptable and palatable to the patient.

The present inventors have found that a pharmaceutical formulation comprising levothyroxine sodium, microcrystalline cellulose with a mean particle size less than 125µm and pregelatinised starch provides a solid dosage form with improved stability and disintegration characteristics that is aesthetically acceptable and palatable to the patient.

Accordingly, the present invention provides a pharmaceutical formulation comprising (a) an effective amount of levothyroxine sodium, (b) microcrystalline cellulose which has a mean particle size of less than 125µm and is present in an amount of 60 to 85% w/w based upon the total weight of the formulation and (c) pregelatinised starch present in an amount of 5 to 30% w/w based upon total weight of the formulation. The pharmaceutical formulations of the present invention have improved stability such that they are stable to the extent that potency decreases by less than 5%, preferably less than 4%, more preferably less than 3% when the pharmaceutical formulation is stored at 25°C and 60% relative humidity for 12 months. The pharmaceutical formulations of the present invention have improved disintegration characteristics such that they have a disintegration time of less than 6 minutes, preferably less than 5 minutes, more preferably less than 4 minutes when tested in the disintegration test as described in the Examples section below.

The chemical name for levothyroxine sodium is sodium (S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propionate. Levothyroxine sodium is the monosodium salt of the levo-rotatory isomer of thyroxine. Levothyroxine sodium may exist as one or more polymorphic forms, for example one or more crystalline forms, amorphous forms, phases, solid solutions and/or mixtures thereof. All such forms of levothyroxine sodium and/or mixtures thereof are encompassed by the present invention. Preferably the

levothyroxine sodium for use in pharmaceutical formulations of the present invention is in hydrated form. More preferably, the levothyroxine sodium for use in pharmaceutical formulations of the present invention is in the pentahydrate form.

- 5 Preferably, the levothyroxine sodium is present in an amount less than 1% w/w based upon the total weight of the formulation, more preferably 0.01-0.30% w/w, even more preferably 0.03-0.25% w/w, most preferably 0.06-0.20% w/w. The minimum amount of levothyroxine sodium can vary, so long as an effective amount is utilised to cause the desired pharmacological effect.

10

- Preferably, the microcrystalline cellulose has a mean particle size of $\leq 100\mu\text{m}$, more preferably $\leq 75\mu\text{m}$, even more preferably $\leq 50\mu\text{m}$. Preferably, the microcrystalline cellulose is selected from microcrystalline cellulose grade 101, 102, or 103, more preferably grade 101 or 102, most preferably grade 101. The term 'Grade 101' as used
15 herein means material with nominal mean particle size $50\mu\text{m}$ and moisture content $\leq 5.0\%$ in accordance with the European Pharmacopeia (2002). The term 'Grade 102' as used herein means material with nominal mean particle size $100\mu\text{m}$ and moisture content $\leq 5.0\%$ in accordance with the European Pharmacopeia (2002). The term 'Grade 103' as
20 used herein means material with nominal mean particle size $50\mu\text{m}$ and moisture content $\leq 3.0\%$ in accordance with the European Pharmacopeia (2002). The term 'Grade 200' as used herein means material with nominal mean particle size $180\mu\text{m}$ and moisture content $\leq 5.0\%$ in accordance with the European Pharmacopeia (2002). Preferably the microcrystalline cellulose is sourced from FMC Corporation, JRS Rettenmaier or Sähne (Germany) or Wei Ming (Taiwan), more preferably Wei Ming (Taiwan).

25

Preferably, the microcrystalline cellulose is present in an amount of 60 to 85% w/w based on the total weight of the formulation, more preferably 65 to 80% w/w, most preferably 70 to 80% w/w.

- 30 The term 'pregelatinised starch' as used herein means partially pregelatinised starch typically containing about 5% of free amylose, 15% of free amylopectin and 80% unmodified starch. It is produced by subjecting moistened starch to mechanical pressure in order to rupture some or all of the starch granules. The resultant material is ground and its moisture content adjusted such that it possesses good flow and compression
35 characteristics. Typical cold water solubility of partially pregelatinised starch, e.g. Starch 1500 (Colorcon) is 10-20%. Pregelatinised starch is further defined in the European Pharmacopeia (2002) which is included herein by reference. Preferably, the pregelatinised starch is present in an amount of 5 to 30% w/w based on the total weight of the formulation, more preferably 10 to 30% w/w, most preferably 15 to 25% w/w.

40

Preferably, the ratio of microcrystalline cellulose:pregelatinised starch is in the range of 2:1 to 15:1, more preferably 2.5:1 to 8:1, most preferably 3:1 to 5:1.

Preferably, the microcrystalline cellulose and pregelatinised starch contain water. Preferably, the water comprises 3-6% w/w based on the total weight of the formulation, more preferably about 4.5% (e.g. 4.5% - 5.0%).

5

Preferably, the pharmaceutical formulation includes one or more glidants/lubricants. Suitable glidants/lubricants for use in the present invention include colloidal silicon dioxide, talc, magnesium stearate, zinc stearate, calcium stearate, sodium stearate fumarate and sodium magnesium lauryl sulphate. Preferably, the glidants/lubricants are selected from one or more of: colloidal silicon dioxide, talc and magnesium stearate.

10

Preferably, the glidant/lubricant is present in an amount 1-10% of the total weight of the formulation, more preferably 2-9% of the total weight of the formulation, most preferably 3-8% of the total weight of the formulation.

15

Preferably, talc is present in an amount 1-5% of the total weight of the formulation, more preferably 2-4% of the total weight of the formulation, most preferably 2.5-3.5% of the total weight of the formulation.

20

Preferably, colloidal anhydrous silica is present in an amount 1-5% of the total weight of the formulation, more preferably 1-3% of the total weight of the formulation, most preferably 1.5-2.5% of the total weight of the formulation.

25

Preferably, magnesium stearate is present in an amount 0.1-5% of the total weight of the formulation, more preferably 0.5-4% of the total weight of the formulation, most preferably 0.8-1.5% of the total weight of the formulation.

30

Preferably, the pH of the pharmaceutical formulation is in the range pH 6.8 to 8.2, preferably pH 7.2 to 7.8 when suspended in water in a ratio water:pharmaceutical formulation of 10:1.

35

The formulations of the invention may, if desired, further include one or more pharmaceutically acceptable excipients. All such excipients must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Pharmaceutically acceptable excipients may include colours, flavours e.g. menthol, sweeteners e.g. mannitol, preservatives, stabilisers, antioxidants and any other excipients known to those skilled in the art.

40

It is to be understood that the present invention covers all combinations of particular and preferred groups described hereinabove.

The present invention provides a pharmaceutical formulation for use in medical therapy, e.g. in the treatment of thyroid hormone disorders in an animal, e.g. a mammal such as a human. Levothyroxine and other thyroid hormones are known to serve as hormone replacement therapy when the thyroid function has been reduced or is completely absent for a variety of disease states, including, hypothyroidism, myxedema, cretinism and obesity, preferably hypothyroidism.

For each of the above-indicated utilities and indications the amount required of levothyroxine sodium will depend on a number of factors including the severity of the condition to be treated and the identity of the recipient and will ultimately be at the discretion of the attendant physician or veterinarian. Typically, a physician will determine the actual dosage which will be most suitable for an individual subject. The specific dose level and frequency of dosage for any particular individual may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy. In general, however, for each of these utilities and indications, a suitable effective dose will be in the range 1.0 to 6.0 μ g per kilogram bodyweight of recipient per day, preferably in the 1.5 to 5.0 μ g per kilogram bodyweight per day (unless otherwise indicated, all weights are calculated with respect to the free base active ingredient).

The desired dose is preferably presented as one, two, three or four sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing about 10 to 300 μ g, preferably 10-200 μ g, more preferably 25-150 μ g, of active ingredient per unit dose form, most preferably 50 μ g or 100 μ g of active ingredient per unit dose form.

For example, a 50 μ g tablet may comprise 0.0425-0.0575mg levothyroxine sodium, 50-60mg microcrystalline cellulose, 12-17mg pregelatinised starch, 2-3mg talc, 1-2mg colloidal anhydrous silica and 0.5-1mg magnesium stearate. A 100 μ g tablet may comprise 0.085-0.115mg levothyroxine sodium, 100-120mg microcrystalline cellulose, 24-34 pregelatinised starch, 4-6mg talc, 2-4mg colloidal anhydrous silica and 1-2mg magnesium stearate.

The pharmaceutical formulation is preferably administered orally and is preferably in the form of a tablet. However, in addition to tablets, the composition according to the present invention may also be administered in the form of capsules, caplets, gelcaps, pills, and any other oral dosage forms known in the pharmaceutical art.

The term "treatment" and derivatives such as "treating" as used herein includes both treatment and prophylaxis. Prophylaxis is relevant in relation to protection against such conditions such as hypothyroidism.

- 5 A further aspect of the invention provides a process for preparing a pharmaceutical formulation according to the invention.

10 The tablet may be prepared either by a wet granulation or by a direct compression process. Preferably a direct compression process is used, e.g. using a conventional high speed rotary press.

15 Preferably, the pharmaceutical formulation is prepared by making an initial preparation of a triturate of levothyroxine sodium and subsequently incorporating the triturate into the tablet formulation. A triturate of levothyroxine sodium comprises levothyroxine sodium and a suitable carrier, e.g. microcrystalline cellulose, wherein the levothyroxine sodium is present in a greater concentration in the triturate than in the final tablet formulation. Preferably, the triturate comprises 2-3% w/w levothyroxine sodium of total weight of triturate. Preparation using a triturate improves distribution of the low concentration of drug throughout the blend and uniformity in the tablets i.e. homogeneous incorporation.

20 Preferably, the process comprises the steps of: (a) preparing a triturate of levothyroxine sodium and microcrystalline cellulose, (b) mixing the triturate with the remaining components of the pharmaceutical formulation, and (c) compression.

25 Levothyroxine sodium can be obtained from the thyroid gland of domesticated animals, or alternatively the hormone can be prepared synthetically. Methods for making active ingredient are disclosed in Hagers Handbuch der pharmazeutischen Praxis, - 5., vollst. Neubearb., Bd.8.Stoffe: E-O / F... Von Bruchhausen; (Hrgs.).Bearb... von M. Albinus - 1993, Springer-Verlag Berlin Heidelberg 1993, pages 733 - 734; S. Rolski, Chemia
30 środków leczniczych, str. 654-655, PZWL, Warszawa 1968. The contents of which are incorporated herein by reference.

35 The formulation may be introduced into a container which is then closed. The container may be sealed, e.g. by LDPE tamper-evident snap fit closures. It may be a single-dose or multi-dose container. The container may be bottles, jars, bags or sachets. Sachets, especially foil sachets (foil-foil blisters), are particularly suitable for single dose packaging. Bottles, particularly high density polyethylene (HDPE) or polypropylene (PP) bottles are particularly suitable for multi-dose packaging.

40 The following examples illustrate aspects of this invention but should not be construed as limiting the scope of the invention in any way.

Examples**Example 1: Preparation of Levothyroxine Sodium Tablets****5 (a) Formulation**

	[kg]
Levothyroxine sodium pentahydrate	0.074
Microcrystalline cellulose	75.0
Pregelatinised starch	20.0
10 Talc	3.0
Colloidal silicon dioxide	2.0
Magnesium stearate	1.0

Manufacturing Process

15 Levothyroxine sodium tablets were manufactured by a direct compression process comprising the following steps:

- preparation of a levothyroxine sodium triturate with a portion of the microcrystalline cellulose by simple blending
- blending the remainder of the microcrystalline cellulose and pregelatinised starch with the levothyroxine sodium triturate to produce a uniform content of active substance;
- 20 - addition of the talc, silicon dioxide colloidal and magnesium stearate, followed by blending to prepare a powder mixture;
- compression of levothyroxine sodium tablets at a crushing strength of 3Kp not less than a resulting strength of 3.5 – 10Kp.

25

(b) Formulation

	[kg]
Levothyroxine sodium pentahydrate	0.074
Microcrystalline cellulose	75.0
30 Pregelatinised starch	20.0
Talc	3.0
Colloidal silicon dioxide	2.0
Magnesium stearate	1.0

35 **Manufacturing Process** The manufacturing process for Example 1(b) differed from Example 1(a) in that a preblend of the remainder of microcrystalline cellulose and colloidal silicon dioxide was made before blending with the levothyroxine sodium triturate and pregelatinised starch.

40 Example 2: Stability of Levothyroxine Sodium Tablets.

Comparative stability studies of levothyroxine sodium tablets were based on testing of levothyroxine sodium and total impurities contents after storage of tablets at (i) 40°C/75%RH, (ii) 30°C/60%RH, and (iii) 25°C/60%RH. Suitable HPLC methods were applied. Stability was measured in terms of levothyroxine sodium content and total impurities content:

Total impurities contents were determined using the assay method for levothyroxine sodium tablets in the British Pharmacopoeia 2002 with a sample concentration of 50µg/ml, sample solvent:methanol and 0.02 M aqueous NaOH (1:1), an injection volume of 100µl and a phase flow rate of 1.5ml/min.

Levothyroxine sodium contents were determined using the assay method for levothyroxine sodium tablets in the British Pharmacopoeia 2002 using a sample concentration of 50µg/ml, sample solvent:methanol and 0.02 M aqueous NaOH (1:1) and phase flow rate of 1.5 ml/min.

The results of these stability tests are provided in tables (A) to (C).

Conclusions

(A) Stability of Levothyroxine Sodium Tablets: comparison of levothyroxine sodium tablets prepared according to Example 1(b) with Eltroxin™ tablets.

The data shows that at 3-9 months after storage a higher levothyroxine sodium content is maintained in tablets according to Example 1(b) than in the marketed formulation of Eltroxin™ and total impurities are lower in tablets according to Example 1(b) than in marketed formulation of Eltroxin™.

(B) Stability of Levothyroxine Sodium Tablets: effect of microcrystalline cellulose particle size.

The data shows that a higher levothyroxine sodium content is maintained and the total impurities are lower when microcrystalline cellulose with a mean particle size of 50µm or 100µm compared to 180µm is used in the levothyroxine sodium formulation.

(C) Stability of Levothyroxine Sodium Tablets: effect of water content.

The data shows that a higher levothyroxine sodium content is maintained in tablets after 3 months storage where the initial water content of the tablets is 4.1 or 4.7% compared to 2.4 or 2.7%.

(A) Stability of Levothyroxine Sodium Tablets: comparison of levothyroxine sodium tablets prepared according to Example 1(b) with Eiltroxin™ tablets.

Levothyroxine sodium tablets	Tablets strength [µg]	Storage conditions	Levothyroxine Sodium contents [%]**					Total impurities contents [%]				
			Storage time [months]					Storage time [months]				
			Initial value	3	6	9	12	Initial value	3	6	9	12
Example 1 (b)	100	40°C/75%RH 30°C/60%RH 25°C/60%RH	101.0	94.3	90.5	-	-	1.2	3.5	4.8	-	-
Example 1 (b)	50	40°C/75%RH 30°C/60%RH 25°C/60%RH	101.4	92.0	84.4	-	-	1.1	3.8	6.1	-	-
Eiltroxin™	100	40°C/75%RH 30°C/60%RH 25°C/60%RH	98.0	89.5	83.4	-	-	1.2	7.5	8.9	-	-

* % to declaration

5 ' - ' not tested

(B) Stability of Levothyroxine Sodium Tablets: effect of microcrystalline cellulose particle size on levothyroxine sodium tablets prepared according to Example 1(b)

Microcrystalline cellulose grade		Mean particle size [μm]	Storage conditions : 40°C/75%RH						
			Levothyroxine Sodium contents [%]*			Total impurities contents [%]			
			Time [weeks]			Time [weeks]			
			2	8	12	2	8	12	
101	50		99.7	98.1	98.3	0.0	2.6	2.8	
			99.6	95.6	95.4	0.6	2.3	1.6	
102	100		95.8	90.2	88.6	4.8	6.1	6.6	
			96.0	90.5	86.8	2.3	5.0	5.5	
200		180	91.6	87.5	80.9	2.1	7.7	-	

* % to initial value (initial value equals 100%)

(C) Stability of Levothyroxine Sodium Tablets: effect of water content on levothyroxine sodium tablets prepared according to Example 1(b)

Tablets strength [µg]	Storage conditions	Loss of drying [%]		Levothyroxine Sodium contents [%]*	
		Storage time [months]		Storage time [months]	
		Initial value	3	Initial value	3
100	40°C/75%RH 30°C/60%RH 25°C/60%RH	4.1	5.1 5.1 4.4	100.6	91.6 97.3 99.5
100	40°C/75%RH 30°C/60%RH 25°C/60%RH	2.7	2.8 2.6 2.7	99.7	83.0 94.3 94.5
50	40°C/75%RH 30°C/60%RH 25°C/60%RH	4.7	5.7 5.1 4.9	101.4	92.0 100.0 99.8
50	40°C/75%RH 30°C/60%RH 25°C/60%RH	2.4	1.6 1.4 1.2	100.6	82.0 90.1 91.6

Example 3: Disintegration of Levothyroxine Sodium Tablets

The disintegration of Levothyroxine Sodium tablets prepared according to Example 1(b) was tested according to the British Pharmacopoeia (BP) 2002 (General Monograph for

5 **Tablets, Uncoated Tablets, Disintegration Test).**

The results are presented in table (D):

(D) Disintegration of Levothyroxine Sodium Tablets

Tablets strength [µg]	Storage conditions	Disintegration time [min, s]				
		Storage time [months]				
		Initial value	3	6	9	12
100	40°C/75%RH	0mins 38secs	2mins 14secs	2mins 00secs	-	-
	30°C/60%RH		0mins 37secs	2mins 52secs	1mins 26secs	0mins 57secs
	25°C/60%RH		0mins 36secs	1mins 00secs	1mins 38secs	0mins 53secs
50	40°C/75%RH	0mins 31secs	1mins 40secs	1mins 56secs	-	-
	30°C/60%RH		0mins 33secs	0mins 32secs	0mins 59secs	1mins 49secs
	25°C/60%RH		0mins 29secs	0mins 46secs	0mins 45secs	0mins 53secs

10 ' - ' not tested

Conclusion**(D) Disintegration of Levothyroxine Sodium Tablets**

15

The data shows that disintegration of tablets prepared according to Example 1(b) is very fast (less than 4 minutes). The pharmacopoeia for uncoated tablets requires disintegration time only less than 15 minutes.

20

Throughout the specification and the claims which follow, unless the context requires otherwise, the word "comprise" and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers but not to the exclusion of any other integer or step or group of integers or steps.

25

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any novel feature or combination of features described

herein. This may take the form of product, composition, process or use claims and may include, by way of example and without limitation, one or more of the following claims.

CLAIMS

1. A pharmaceutical formulation comprising: (a) an effective amount of levothyroxine sodium, (b) microcrystalline cellulose which has a mean particle size of less than 125µm and is present in an amount of 60 to 85% w/w based upon the total weight of the formulation, and (c) pregelatinised starch present in an amount of 5 to 30% w/w based upon total weight of the formulation.
2. A pharmaceutical formulation as claimed in claim 1 wherein the microcrystalline cellulose has a mean particle size less than or equal to 100µm.
3. A pharmaceutical formulation as claimed in claim 1 or claim 2 wherein the ratio of microcrystalline cellulose:pregelatinised starch is in the range of 2:1 to 15:1.
4. A pharmaceutical composition as claimed in any one of claims 1-3 wherein the microcrystalline cellulose and pregelatinised starch comprise water which is present in an amount 3-6% w/w based on the total weight of the formulation.
5. A pharmaceutical formulation as claimed in any one of claims 1-4 wherein the levothyroxine sodium is hydrated.
6. A pharmaceutical formulation as claimed in claim 5 wherein the levothyroxine sodium is the pentahydrate form.
7. A pharmaceutical formulation as claimed in any one of claims 1-6 which further comprises one or more glidant/lubricants.
8. A pharmaceutical formulation as claimed in claim 7 wherein the glidant/lubricants are selected from: colloidal anhydrous silica, talc and/or magnesium stearate.
9. A pharmaceutical formulation as claimed in any one of claims 1-8 which is stable to the extent that potency decreases by less than 5% when the pharmaceutical formulation is stored at 25°C and 60% relative humidity for 12 months.
10. A pharmaceutical formulation as claimed in any of claims 1-9 in unit dose form.
11. A pharmaceutical formulation as claimed in claim 10 wherein the unit dose form is a tablet.
12. A pharmaceutical formulation as claimed in any of claims 1-11 for use in medical therapy.

13. A pharmaceutical formulation as claimed in any of claims 1-11 for use in the treatment of thyroid hormone disorders in a mammal, such as man.

5 14. Use of a pharmaceutical formulation as claimed in any of claims 1-11 in the manufacture of a medicament for the treatment of thyroid hormone disorders in a mammal such as man.

10 15. A method of treating thyroid hormone disorders comprising administering a pharmaceutical formulation as claimed in any of claims 1-11.

15 16. A process for preparing a pharmaceutical formulation as claimed in any of claims 1-11 comprising (a) preparing a triturate of levothyroxine sodium, (b) mixing the triturate with the remaining components of the pharmaceutical formulation, and (c) compression.

20

ABSTRACT

There is provided a stable pharmaceutical formulation comprising (a) an effective amount of levothyroxine sodium, (b) microcrystalline cellulose which has a mean particle size of less than 125µm and is present in an amount of 60 to 85% w/w based upon the total weight of the formulation, and (c) pregelatinised starch present in an amount of 5 to 30% w/w based upon total weight of the formulation. There is also provided a process for the preparation of such a formulation.

DCA
PCT/EP2004/007667



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.